Marquette Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Marquette Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,166	Closed	-$158K	–	156
2024 Q4	$158K	Hold	47,166	–	–	0.03%	102
2024 Q3	$158K	Hold	47,166	–	–	0.03%	111
2024 Q2	$156K	Hold	47,166	–	–	0.03%	83
2024 Q1	$191K	Hold	47,166	–	–	0.03%	75
2023 Q4	$144K	Buy	47,166 +22,301	+90%	+$67.5K	0.03%	88
2023 Q3	$74.6K	Hold	24,865	–	–	0.02%	123
2023 Q2	$93K	Hold	24,865	–	–	0.02%	122
2023 Q1	$83.3K	Buy	+24,865	New	+$101K	0.02%	124

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marquette Asset Management's AVIR Position: Q1 2025 in Review

Marquette Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 47,166 shares — an estimated $158K sold.

Marquette Asset Management first reported a position in AVIR in Q1 2023 and held it in 8 quarters. The position peaked at $191K in Q1 2024. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

Marquette Asset Management reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Marquette Asset Management sold 47,166 Atea Pharmaceuticals shares in Q1 2025, an estimated $158K.
Marquette Asset Management first reported a position in Atea Pharmaceuticals in Q1 2023 and held it in 8 quarters.
Marquette Asset Management's Atea Pharmaceuticals position peaked at $191K in Q1 2024.
103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on Marquette Asset Management's 13F filing for Q1 2025, filed 9 Apr 2025.